Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
NightstaRx Ltd, a Biogen Company
This study was previously posted by NightstaRx Ltd. In October 2020, sponsorship of the trial was transferred to Biogen.
Age
18–any
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
CHM Participants
a. Have participated in and exited from an interventional study that investigated the safety and efficacy of a sub-retinal injection of BIIB111 for CHM.
XLRP Participants
a. Have received a sub-retinal injection of BIIB112 for XLRP and have exited an antecedent study.
You may not be if
a. In the opinion of the Investigator and/or the Sponsor, it is not in the participant's best interest to participate in the study.
Clareo Health | Long-term Safety and Efficacy Follow-up of BIIB111 for the Treatment of Choroideremia and BIIB112 for the Treatment of X-Linked Retinitis Pigmentosa
